Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Intarcia Therapeutics revenue
Intarcia Therapeutics's revenue is $70.0 million.
What is Intarcia Therapeutics's revenue?
- Intarcia Therapeutics has 44 employees, and the revenue per employee ratio is $1,590,909.
- Intarcia Therapeutics peak revenue was $70.0M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Intarcia Therapeutics financing
Intarcia Therapeutics received early financing of $2.0M on 1998-08-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $2M | 08/1998 |
| Series B | $12.1M | 04/1999 |
| Series C | $38M | 09/2000 |
| Series D | $43M | 06/2003 |
| Series E | $50M | 12/2004 |
| Debt Financing | $10M | 04/2005 |
| Series Unknown | $50M | 03/2007 |
| Series Unknown | $9M | 01/2010 |
| Series Unknown | $14.5M | 05/2010 |
| Debt Financing | $5M | 09/2010 |
| Debt Financing | $45.8M | 08/2012 |
| Debt Financing | $50M | 11/2012 |
| Series Unknown | $160M | 11/2012 |
| Series Unknown | $200M | 04/2014 |
| Undisclosed | $225M | 04/2015 |
| Debt Financing | $75M | 05/2016 |
| Series E | $215M | 09/2016 |
| Series E | $206M | 12/2016 |
| Series E | $200M | 09/2017 |
| Debt Financing | $73.1M | 02/2019 |
Intarcia Therapeutics investors
| Investors | Security type |
|---|---|
| InterWest Partners | Series B |
| Alta Partners | Series B |
| InterWest Partners | Series C |
| Alta Partners | Series C |
| New Enterprise Associates (NEA) | Series D |
| Venrock | Series D |
| InterWest Partners | Series D |
| Alta Partners | Series D |
| New Enterprise Associates (NEA) | Series E |
| Venrock | Series E |
| InterWest Partners | Series E |
| Alta Partners | Series E |
| GGV Capital | Series E |
| Silicon Valley Bank | Debt Financing |
| Horizon Technology Finance | Debt Financing |
| New Enterprise Associates (NEA) | Series Unknown |
| QUADRILLE CAPITAL | Series Unknown |
| Venrock | Series Unknown |
| Omega Funds | Series Unknown |
| Alta Partners | Series Unknown |
| GGV Capital | Series Unknown |
| New Leaf Venture Partners | Series Unknown |
| Greenspring Associates | Series Unknown |
| New Enterprise Associates (NEA) | Debt Financing |
| Venrock | Debt Financing |
| New Leaf Venture Partners | Debt Financing |
| New Enterprise Associates (NEA) | Debt Financing |
| Venrock | Debt Financing |
| New Leaf Venture Partners | Debt Financing |
| New Enterprise Associates (NEA) | Series Unknown |
| Baupost Group | Series Unknown |
| Venrock | Series Unknown |
| GGV Capital | Series Unknown |
| Marker | Series Unknown |
| Farallon Capital Management | Series Unknown |
| New Leaf Venture Partners | Series Unknown |
| Alger | Series Unknown |
| QUADRILLE CAPITAL | Series Unknown |
| Foresite Capital | Series Unknown |
| RA Capital Management | Series Unknown |
| Farallon Capital Management | Series Unknown |
| New Leaf Venture Partners | Series Unknown |
| MidCap Financial | Debt Financing |
| Silicon Valley Bank | Debt Financing |
| Kayon Partners | Series E |
| Baupost Group | Series E |
| NXT Ventures | Series E |
| BAILLIE GIFFORD & CO | Series E |
| Foresite Capital | Series E |
| The Pritzker Organization | Series E |
| Fidelity Investments | Series E |
| RA Capital Management | Series E |
| GWC Innovator Fund | Series E |
| Bill & Melinda Gates Foundation | Series E |
Intarcia Therapeutics competitors
Intarcia Therapeutics's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Intarcia Therapeutics's smallest competitor is Seagen with revenue of $2.0B last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,389 |
| Amgen | $93,349 | $33.4B | 22,000 | 535 |
| Zoetis | $87,092 | $9.3B | 11,300 | 206 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 576 |
| Merck | $90,328 | $64.2B | 74,000 | 1,533 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 197 |
| Regeneron | $85,589 | $14.2B | 9,123 | 343 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Seagen | $85,008 | $2.0B | 900 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Intarcia Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Intarcia Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Intarcia Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Intarcia Therapeutics. The data presented on this page does not represent the view of Intarcia Therapeutics and its employees or that of Zippia.
Intarcia Therapeutics may also be known as or be related to INTARCIA THERAPEUTICS, INC, Intarcia Therapeutics, Intarcia Therapeutics Inc. and Intarcia Therapeutics, Inc.